CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 6.65
+0.22 (3.42%)
At close: Mar 6, 2026
CStone Pharmaceuticals Employees
CStone Pharmaceuticals had 131 employees as of June 30, 2025. The number of employees decreased by 4 or -2.96% since the number was reported on December 31, 2024.
Employees
131
Change
-4
Growth
-2.96%
Revenue / Employee
1.69M HKD
Profits / Employee
-3.15M HKD
Market Cap
9.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 131 | -4 | -2.96% |
| Dec 31, 2024 | 135 | -95 | -41.30% |
| Dec 31, 2023 | 230 | -246 | -51.68% |
| Dec 31, 2022 | 476 | -135 | -22.09% |
| Dec 31, 2021 | 611 | 141 | 30.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 2,156 |
| CK Life Sciences Int'l., (Holdings) | 1,935 |
| Keymed Biosciences | 1,469 |
| Everest Medicines | 722 |
| Lepu Biopharma | 546 |
| Alphamab Oncology | 484 |
| CARsgen Therapeutics Holdings | 371 |
| Abbisko Cayman | 226 |
CStone Pharmaceuticals News
- 12 days ago - CStone Secures MHRA Approval For Sugemalimab In Stage III NSCLC In UK - Nasdaq
- 12 days ago - CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC - PRNewsWire